Prevention and treatment of amyloidogenic disease
AssigneesNeuralab Limited, Athena Neurosciences, Inc.
InventorDale B. Schenk
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is Aβ peptide or an antibody thereto.
Claims63
A pharmaceutical composition comprising an agent effective to induce an immunogenic response against Aβ in a patient, and a pharmaceutically acceptable adjuvant.
The pharmaceutical composition of any of the preceding claims, wherein the Aβ or fragment is a component of a particle.
A method of preventing or treating a disease characterized by amyloid deposit in a patient, comprising:
- administering an agent effective to induce an immune response against a peptide component of an amyloid deposit in the patient.
The method of any of the preceding claims, wherein the disease is Alzheimer's disease.
The method of any of the preceding claims, wherein the patient is asymptomatic.
The method of any of the preceding claims, wherein the patient is under 50.
The method of any of the preceding claims, wherein the patient has inherited risk factors indicating susceptibility to Alzheimer's disease.
The method of any of the preceding claims, wherein the agent comprises Aβ peptide or an active fragment thereof.
The method of any of the preceding claims, wherein the agent is Aβ peptide or an active fragment thereof.
The method of any of the preceding claims, wherein the Aβ peptide is Aβ42.
The method of claim any of the preceding claims, wherein the immune response comprises antibodies that bind to the Aβ peptide.
The method of any of the preceding claims, wherein the immune response comprises T-cells that bind to the Aβ peptide as a component of an MHC I or MHC II complex.
The method of any of the preceding claims, wherein the agent is administered orally, subcutaneously, intramuscularly, topically or intravenously.
The method of any of the preceding claims, wherein the agent is administered intramuscularly or subcutaneously.
The method of any of the preceding claims, further comprising screening a library of compounds to identify a compound reactive with antibodies to Aβ, and administering the
The method of any of the preceding claims, further comprising monitoring the patient for the immune response.
The method of any of the preceding claims, further comprising administering an adjuvant that enhances the immune response to the Aβ peptide.
A method of preventing or treating Alzheimer's disease comprising administering an effective dose of Aβ peptide to a patient.
Use of Aβ peptide, or an antibody thereto, in the manufacture of a medicament for prevention or treatment of Alzheimer's disease.
A composition comprising Aβ or a fragment linked to a conjugate molecule that promotes delivery of Aβ to the bloodstream of a patient and/or promotes an immune response against Aβ.
A pharmaceutical composition comprising an agent effect to induce an immunogenic response against Aβ in a patient with the proviso that the composition is free of Complete Freund's adjuvant.
A composition comprising a viral vector encoding Aβ or a fragment thereof effective to induce an immune response against Aβ.
A method of assessing efficacy of an Alzheimer's treatment method in a patient, comprising
- determining a baseline amount of antibody specific for Aβ peptide in tissue sample from the patient before treatment with an agent,
- comparing an amount of antibody specific for Aβ peptide in the tissue sample from the patient after treatment with the agent to the baseline amount of Aβ peptide-specific antibody,
- wherein an amount of Aβ peptide-specific antibody measured after the treatment that is significantly greater than the baseline amount of Aβ peptide-specific antibody indicates a positive treatment outcome.
A method of assessing efficacy of an Alzheimer's treatment method in a patient, comprising
- determining a baseline amount of antibody specific for Aβ peptide in tissue sample from a patient before treatment with an agent;
- comparing an amount of antibody specific for Aβ peptide in the tissue sample from the subject after treatment with the agent to the baseline amount of Aβ peptide-specific antibody,
- wherein a reduction or lack of significant difference between the amount of Aβ peptide-specific antibody measured after the treatment compared to the baseline amount of Aβ peptide-specific antibody indicates a negative treatment outcome.
A method of assessing efficacy of an Alzheimer's treatment method in a patient, comprising
- determining a control amount of antibody specific for Aβ peptide in tissue samples from a control population,
- comparing an amount of antibody specific for Aβ peptide in a tissue sample from the patient after administering an agent to the control amount of Aβ peptide-specific antibody,
- wherein an amount of Aβ peptide-specific antibody measured after the treatment that is significantly greater than the control amount of Aβ peptide-specific antibody indicates a positive treatment outcome.
A method of assessing efficacy of an Alzheimer's treatment method in a patient, comprising
- determining a control amount of antibody specific for Aβ peptide in tissues samples from a control population,
- comparing an amount of antibody specific for Aβ peptide in a tissue sample from the patient after administering an agent to said control amount of Aβ peptide-specific antibody,
- wherein a lack of significant difference between the amount of Aβ peptide-specific antibody measured after beginning said treatment compared to the control amount of Aβ peptide-specific antibody indicates a negative treatment outcome.
A method of monitoring Alzheimer's disease or susceptibility thereto in a patient, comprising:
- detecting an immune response against Aβ peptide in a sample from the patient.
A method of assessing efficacy of an Alzheimer's treatment method in a patient, comprising
- determining a value for an amount of antibody specific for Aβ peptide in tissue sample from a patient who has been treated with an agent;
- comparing the value with a control value determined from a population of patient experiencing amelioriation of, or freedom from, symptoms of Alzheimer's disease due to treatment with the agent;
- wherein a value in the patient at least equal to the control value indicates a positive response to treatment.
Dependencies are inferred from the claim text.